A study investigating the effect of different approved medications on how the body processes the study compound RO7795081. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control.

2024-517360-37-00 Protocol BP45670 Human pharmacology (Phase I) - Other Ended

Start 22 Nov 2024 · End 28 May 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BP45670

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 50
Countries 1
Sites 1

Type 2 Diabetes and obesity

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
22 Nov 2024 → 28 May 2025
Decision date (initial)
2024-11-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Type 2 Diabetes and obesity

VersionLevelCodeTermSystem organ class
21.1 LLT 10045260 Type II obese diabetic 10027433

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 50 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharma Bio-Research Group
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-11-22 2025-05-28 2024-11-22 2025-03-17

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-23 Netherlands Acceptable
2024-11-08
2024-11-08
2 SUBSTANTIAL MODIFICATION SM-1 2025-04-04 Netherlands Acceptable
2025-04-18
2025-04-18